Latest:
Dr. Obeid on the KATHERINE Trial in HER2-Positive Breast Cancer
Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Elihu H. Estey, MD
Latest:
Dr. Estey Discusses the FDA Approval Process
Elihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, discusses a potential change to the FDA approval process as it relates to Mylotarg (gemtuzumab ozogamicin).
Elisa Krill-Jackson, MD
Latest:
Beyond Hyperglycemia: Complete Safety Management for PI3K Inhibitor Combinations
Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.
Elisabeth Weiss, MD
Latest:
Diffusion-Weighted MRI Studies Explored at VCU Massey Cancer Center
The Department of
Radiation Oncology
at Virginia Commonwealth
University
Massey Cancer Center has
long been at the forefront
worldwide in the development
of various radiation
therapy technologies that
are now considered standard
and have become widely available.
Elizabeth Bossart, PhD
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Elizabeth Franzmann, MD
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Elizabeth J. Shpall, MD
Latest:
Dr. Shpall on Therapeutic Agents for the Treatment of CLL
Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.